Samelisant (SUVN-G3031) for the Treatment of Cataplexy in Patients With Narcolepsy Type-one: Rationale and Study Design of a Phase-two Study (P6-14.008) | Synapse
June 13, 2026
Samelisant (SUVN-G3031) for the Treatment of Cataplexy in Patients With Narcolepsy Type-one: Rationale and Study Design of a Phase-two Study (P6-14.008)
Key Points
This research aims to assess the efficacy of Samelisant in treating cataplexy for narcolepsy type-one patients.
Phase-two clinical trial design to evaluate treatment outcomes
Focus on patients diagnosed with narcolepsy type-one
Involves assessment of cataplexy symptoms management
Results will determine the effectiveness of Samelisant compared to the current treatment options
Expectations include improvement in cataplexy frequency and severity
Abstract
To evaluate the potential utility of Samelisant for the management of cataplexy